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NF-κBAsthma is a chronic inﬂammatory condition. Inhibition of the ubiquitin–proteasome system offers promise
as a anti-inﬂammatory strategy, being responsible for the degradation of key proteins involved in crucial
cellular functions, including gene expression in inﬂammation (e.g. inhibitory IκB-α and the endogenous
MAPK deactivator —MKP-1). As MKP-1 inhibits MAPK-mediated pro-remodeling functions in human airway
smooth muscle (ASM; a pivotal immunomodulatory cell in asthma) in this study we investigate the effect of
the proteasome inhibitor MG-132 on MKP-1 and evaluate the anti-inﬂammatory effect of MG-132 on
cytokine secretion from ASM cells. Examining the time-course of induction of MKP-1 mRNA and protein by
MG-132 (10 μM) we show that MKP-1 mRNA was ﬁrst detected at 30 min, increased to signiﬁcant levels by
4 h, resulting in a 12.6±1.5-fold increase in MKP-1 mRNA expression by 24 h (Pb0.05). MKP-1 protein
levels corroborate the mRNA results. Investigating the effect of MG-132 on secretion of the cytokine IL-6 we
show that while short-term pretreatment with MG-132 (30 min) partially reduced TNFα-induced IL-6 via
inhibition of IκB-α degradation and the NF-κB pathway, longer-term proteasome inhibition (up to 24 h)
robustly upregulated MKP-1 and was temporally correlated with repression of p38-mediated IL-6 secretion
from ASM cells. Moreover, utilizing a cytokine array we show that MG-132 represses the secretion of
multiple cytokines implicated in asthma. Taken together, our results demonstrate that MG-132 upregulates
MKP-1 and represses cytokine secretion from ASM and highlight the potential of the proteasome as a
therapeutic target in asthma.ersity of Sydney, NSW 2006
.
mmit).
ll rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Introduction
Asthma is a chronic inﬂammatory condition that is characterized
by reversible airway obstruction, airway hyper-responsiveness and
airway remodeling. It is amulti-faceted condition involving numerous
cells, pro-inﬂammatorymediators and signalingmolecules. TheMAPK
phosphoproteins are critical signaling molecules that drive pro-
inﬂammatory pathways in asthma [1,2].
The MAPK superfamily of signaling molecules (p38, ERK and JNK)
are serine/threonine protein kinases that when activated can
phosphorylate numerous downstream effectors, including transcrip-
tion factors, cytoskeletal proteins and other phosphoproteins, to play
a crucial role in a wide variety of cellular functions ranging from
proliferation, migration and synthesis of ﬁbrotic and inﬂammatory
proteins (including cytokines). Thus, MAPKs have emerged as critical
pathways that drive development of airway remodeling to signiﬁ-
cantly contribute to asthma pathophysiology [1,2]. Thus, inhibition ofMAPK has emerged as an attractive strategy for reversing inﬂamma-
tion and remodeling in a wide variety of chronic inﬂammatory
conditions, including asthma.
Cellular function is profoundly affected by both strength and
duration of MAPK activation, which must be strictly controlled to
modulate functional outcome. This crucial negative feedback control
is achieved by MKPs, a family of endogenous dual-speciﬁcity MAPK
phosphatases (also known as dual-speciﬁcity phosphatases (DUSPs)
[3,4]. We [5,6] and others [7,8] have recently uncovered the key role
played by MKP-1 in the inhibition of MAPK-mediated pro-remodeling
functions in airway smooth muscle (ASM) cells; a pivotal immuno-
modulatory cell in asthma. Thus, because MKP-1 serves a crucial
negative feedback role in regulating the strength and duration of pro-
inﬂammatory signal transduction, discovering mechanisms to regu-
late the protein level or enzymatic activity of this endogenous MAPK
deactivator may be exploited as a novel anti-inﬂammatory strategy in
asthma and airway remodeling.
MKP-1 is a 367 amino acid protein expressed by an immediate-
early gene [9]. MKP-1 expression is controlled at multiple steps,
broadly divided into three levels: transcriptional, post-transcriptional
andpost-translational. Diverse stimuli can induceMKP-1 transcription
417J.P. Moutzouris et al. / Biochimica et Biophysica Acta 1803 (2010) 416–423to rapidly upregulate MKP-1 protein [10]. However, the increase in
MKP-1 protein levels is transient, as MKP-1 protein (expressed as a
result of increased transcription and/or mRNA stability) then under-
goes rapid degradation by the proteasomal machinery [11,12]. In this
study, we aim to increase MKP-1 by inhibiting the ubiquitin–
proteasome system with the cell-permeable, reversible proteasome
inhibitor MG-132.
The ubiquitin–proteasome system is responsible for the degrada-
tion of key proteins involved in crucial cellular functions, including
those responsible for gene expression in inﬂammation (including
inhibitory IκB-α, as well as MKP-1, among others [13]); thus,
proteasome inhibition has emerged as a potential pharmacother-
apeutic strategy for treating inﬂammatory processes [13]. Since the
approval of the proteasome inhibitor bortezomib in 2003 for the
treatment of multiple myeloma, a number of structurally and
mechanistically distinct proteasome inhibitors have been trialed in
the treatment of cancer, autoimmune and inﬂammatory diseases,
myocardial infarction, and ischemic brain injury [14,15]. However, the
potential of proteasome inhibition as an anti-inﬂammatory strategy in
asthma has been comparatively less well-studied. Intriguingly,
proteasomal inhibition has been shown to reduce cyclin D1 in ASM
cells in vitro, a critical cell cycle protein controlling ASM hyperplasia
[16], eosinophil chemotaxis in vitro [17] and eosinophilia in an in vivo
animal model of asthma [18]; all hallmarks of asthma. In a recent
study, proteasome inhibition was shown to reverse the reduction of
histone deacetylase 2 (HDAC2) abundance in cells from human
airway and mouse lung [19]. As HDAC2 reduction is associated with
steroid resistance in severe asthmatics and patients with chronic
obstructive pulmonary disease, further studies exploring the potential
of proteasome inhibition in inﬂammatory lung diseases, such as
asthma, are warranted.
Our study is theﬁrst to examine the effect of proteasomal inhibition
on the upregulation of the endogenousMAPKdeactivator –MKP-1 – in
a human cell with relevance in asthma. We examined the temporal
kinetics of MKP-1 mRNA and protein expression by MG-132 induced
by the proteasome inhibitor MG-132 and evaluated the anti-
inﬂammatory effect of MG-132 on cytokine secretion from human
ASM cells. Our results demonstrate that MG-132 upregulates MKP-1
mRNA and protein expression and repress cytokine secretion from
ASM cells; underscoring the potential of the proteasome as a
therapeutic target in asthma.
2. Materials and methods
2.1. Reagents
PD98059, SB203580, and SP600125 were purchased from Calbio-
chem (San Diego, CA). All other reagents used in this study, including
MG-132, were purchased from Sigma-Aldrich (St. Louis, MO), unless
otherwise speciﬁed.
2.2. Cell culture
Human bronchi were obtained from patients undergoing surgical
resection for carcinoma or lung transplant donors in accordance with
procedures approved by the South West Sydney Area Health Service
and the Human Ethics Committee of the University of Sydney. ASM
cells were dissected, puriﬁed and cultured as previously described by
Johnson et al. [20]. A minimum of three different ASM primary cell
lines were used for each experiment.
2.3. Real-time RT-PCR
Total RNA was extracted using the RNeasy Mini Kit (Qiagen
Australia, Doncaster, VIC, Australia) and reverse transcription per-
formed by using the RevertAid First strand cDNA Synthesis Kit(Fermentas Life Sciences, Hanover, MD) as per the manufacturer's
protocol for the use of random hexamer primers. MKP-1 mRNA levels
weremeasured using real-time RT-PCR on an ABI Prism 7000 (Applied
Biosystems, Foster City, CA) with a MKP-1 primer set (Assays on
Demand, dual-speciﬁcity phosphatase 1, Hs00610256_g1; Applied
Biosystems) and the eukaryotic 18 S rRNA endogenous control probe
(Applied Biosystems) and subjected to the following cycle para-
meters: 50 °C for 2 min, 1 cycle; 95 °C for 10 min, 1 cycle; 95 °C for
15 s, 60 °C for 1 min, 40 cycles.
2.4. Western blotting
Western blotting was performed using rabbit polyclonal IgG
antibodies against MKP-1 (M18: Santa Cruz Biotechnology, Santa
Cruz, CA), IκB-α (C-21: Santa Cruz Biotechnology), total and
phosphorylated p38 (Thr180/Tyr182), total and phosphorylated ERK
(Thr202/Tyr204), total and phosphorylated JNK (Thr183/Tyr185). All
MAPK antibodies were from Cell Signaling Technology (Danvers, MA).
α-tubulin was used as the loading control (mouse monoclonal IgG1,
DM1A: Santa Cruz). Primary antibodies were detected with goat anti-
mouse or anti-rabbit HRP-conjugated secondary antibodies (Cell
Signaling Technology) and visualized by enhanced chemilumines-
cence (PerkinElmer, Wellesley, MA).
2.5. ELISAs and cytokine arrays
Cell supernatants were collected and stored at −20 °C for later
analysis by ELISA or cytokine array. IL-6 (BD Biosciences Pharmingen,
Franklin Lakes, NJ: detection limit, 7.8 pg/ml) and IL-8 (BD Bios-
ciences Pharmingen: detection limit, 15.6 pg/ml) ELISAs were
performed according to the manufacturer's instructions. The human
cytokine array (Proteome Proﬁler™ Array Human Cytokine Array
Panel A, ARY005: R&D Systems, Minneapolis, MN) was used to
simultaneously detect the relative levels of 36 different cytokines,
chemokines, and acute phase proteins. The array was performed
according to the manufacturer's instructions. Levels of proteins were
visualized by chemiluminescence and within a linear range of
exposure quantiﬁed by Quantity One® software (Bio-Rad, Hercules,
CA). The protein levels on each array were standardized against an
internal positive control on the array.
2.6. Luciferase assays
The NF-κB reporter vector, pNF-κB-Luc, was purchased from
Clontech (Mountain View, CA). Transient transfection of ASM cells
was performed as described previously [21] and luciferase activity
assessed according to manufacturer's instructions (Promega, Madi-
son, WI).
2.7. Statistical analysis
Statistical analysis was performed using Student's unpaired t test. P
valuesb0.05were considered signiﬁcant. Data representmean+SEM.
3. Results
3.1. MG-132 upregulates MKP-1 mRNA and protein
To examine the time-course of induction of MKP-1 mRNA and
protein expression by MG-132, growth-arrested ASM cells were
treated with vehicle or the proteasome inhibitor MG-132 (10 μM) for
0, 5, 10, 30 and 60 min and 2, 4, 8 and 24 h. The concentration of MG-
132 has been used previously in ASM cells [22]. As shown in Fig. 1A,
MG-132 induced a small increase in MKP-1 mRNA expression as early
as 30 min after treatment with MG-132; although this increase was
not signiﬁcantly different from the vehicle control. However, after 4 h
Fig. 1.MG-132 upregulates MKP-1 mRNA and protein. (A) To examine the time-course
of induction of MKP-1 mRNA by MG-132, growth-arrested ASM cells were treated with
vehicle (empty histograms) or MG-132 (10 μM: ﬁlled histograms) for 0, 5, 10, 30 and
60 min and 2, 4, 8 and 24 h, and MKP-1 mRNA expression was quantiﬁed by real-time
RT-PCR (results expressed as fold increase over 0 min). Statistical analysis was
performed using the Student's unpaired t test (where * denotes signiﬁcant upregulation
induced by MG-132 (Pb0.05)). Data are mean+SEM values from n=3 replicates.
(B) To examine the upregulation of MKP-1 protein induced by MG-132 over time,
growth-arrested ASM cells were treated with vehicle or MG-132 (10 μM) for 0, 5, 10, 30
and 60 min and 2, 4, 8 and 24 h. Cells were then lysed and analyzed byWestern blotting
using rabbit polyclonal IgG antibodies against MKP-1. α-tubulin was used as the
loading control. Results are representative Western blots from n=6 primary ASM cell
lines.
Fig. 2. MG-132 increases MKP-1 via an ERK-independent signaling pathway.
(A) Growth-arrested ASM cells were pretreated with vehicle or PD98059 (10 μM) for
30 min, then treated with MG-132 (10 μM) for 0, 5, 10, 30 and 60 min and 2, 4, 8 and
24 h. Cells were then lysed and analyzed by Western blotting using rabbit polyclonal
IgG antibodies against phosphorylated (Thr202/Tyr204) and total ERK, compared to
MKP-1. α-tubulin was used as the loading control. Results are representative Western
blots from n=4 primary ASM cell lines. (B) Growth-arrested cells were pretreated with
vehicle, actinomycin D (5 μg/ml) or PD98059 (10 μM) for 30 min and then either left
untreated, or treated with MG-132 (10 μM) for 24 h. Cells were then lysed and protein
levels of MKP-1 were determined by Western blotting. α-tubulin was used as the
loading control. Results are representative Western blots from n=4 primary ASM cell
lines.
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(Pb0.05), resulting in a 12.6±1.5-fold increase in MKP-1 mRNA
expression by 24 h (Fig. 1A). The levels of MKP-1 protein corroborate
the mRNA results; MKP-1 was detected as early as 1–2 h after
treatment with MG-132, increased over time and was robustly
upregulated by 24 h (Fig. 1B).
3.2. MG-132 increases MKP-1 via an ERK-independent signaling
pathway
Our results corroborate earlier studies where MG-132 was shown
to upregulate MKP-1 protein via increased MKP-1 mRNA expres-
sion [23], in addition to inhibiting proteasomal degradation [11].
Interestingly, in cell types apart from ASM, MKP-1 mRNA expression
has been shown to occur via an ERK-mediated pathway [24]. To
investigate whether MG-132 increase MKP-1 via a ERK-dependent
signaling pathway in ASM cells, we ﬁrst examined the kinetics of ERK
phosphorylation in cells treated with MG-132 in the absence and
presence of a speciﬁc inhibitor of the ERK pathway — PD98059 (at
10 μM). As shown in Fig. 2A, pretreatment with PD98059 inhibited the
temporal activation of ERK following treatment with MG-132,
measured from 0 min to 24 h (Fig. 2C), but had no effect on MKP-1
protein levels. MG-132 induced a rapid and sustained activation of
ERK; ERK phosphorylation occurred within 5 min and achieved peak
phosphorylation by 30 min. MG-132 does not activate JNK or p38 inASM cells (data not shown). Secondly, we pretreated ASM cells with
the transcription inhibitor actinomycin D, and compared the resultant
effect on MG-132-induced MKP-1 protein with cells pretreated with
the ERK inhibitor PD98059. As shown in Fig. 2B, pretreatment with
actinomycin D completely inhibited the upregulation of MKP-1
protein at 24 h, conﬁrming that transcription is involved in MKP-1
mRNA and protein upregulation induced by MG-132. In comparison,
PD98059 had no effect on MKP-1 protein induced by MG-132
(Fig. 2B). Collectively our results demonstrate that MG-132 induces
ERK phosphorylation, however ERK activation does not contribute to
the upregulation of MKP-1 by MG-132.
3.3. MG-132 inhibits TNFα-induced IL-6, but not IL-8 secretion
Because we demonstrated proteasomal inhibition was an effective
way to upregulateMKP-1 in ASM cells, we now sought to examine the
effect of this upregulation on cytokine secretion. We focused on IL-6
and IL-8 secretion, two important cytokines secreted from ASM cells
[5,21,25]. Growth-arrested ASM cells were pretreated with vehicle or
MG-132 (10 μM) for 30 min, and then stimulated with TNFα (10 ng/
ml) for 24 h. Cell supernatants were collected and IL-6 and IL-
8 concentrations were determined by ELISA. Pretreatment of ASM
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induced IL-6 secretion (Fig. 3A), but had no signiﬁcant effect on IL-
8 secretion from ASM cells (Fig. 3B).
3.4. Molecular mechanisms underlying the effect of short-term
pretreatment with MG-132 on cytokine secretion
We now sought to investigate the molecular mechanisms
underlying the repressive effect of short-term pretreatment (i.e.
30 min) with MG-132 on cytokine secretion from ASM cells. Our
previous publications have underscored the importance of the p38
MAPK signaling pathway in TNFα-induced IL-6 and IL-8 secretion
from ASM cells [5,21,25]. Because the duration and intensity of MAPK
signaling is sensitively controlled by the temporal induction of the
endogenous MAPK deactivator –MKP-1 –we nowwished to examine
whether MG-132 inhibits MAPK-mediated synthetic function in ASM
cells by upregulating MKP-1 and shortening the temporal phosphor-
ylation of MAPKs. In the current study (Fig. 3A), we have shown that
30 min pretreatment with MG-132 signiﬁcantly inhibited TNF-
induced IL-6 secretion from ASM cells. Here (Fig. 4), we explored
whether MKP-1 induced by short-term pretreatment with MG-132
was responsible for the anti-inﬂammatory effect.
In Fig. 4A, we examined the temporal activation of MAPKs by
TNFα, in the absence and presence of MG-132 pretreatment. In
corroboration of earlier work [5], we show that TNFα transiently
activates MAPK family members and that TNFα alone can also induce
transient upregulation of MKP-1. However, pretreatment with MG-
132 did not inhibit the temporal proﬁle of MAPK activation. The
critical time point for MKP-1 to interrupt MAPK signaling and to have
a repressive effect on cytokine secretion in ASM cells appears to be at
30 min after stimulation [5,7]. At this time point (see 30 min in
Fig. 4A), there were no discernible differences in MKP-1 levels in cells
pretreated without and with MG-132. By 60 min however, there was
more MKP-1 protein present in cells treated with TNFα and MG-132Fig. 3. MG-132 inhibits TNFα-induced IL-6, but not IL-8 secretion. Growth-arrested
ASM cells were pretreated with vehicle or MG-132 (10 μM) for 30 min and then
stimulated with TNFα (10 ng/ml) for 24 h. Cell supernatants were collected and (A) IL-
6 and (B) IL-8 concentrations determined by ELISA. Statistical analysis was performed
using the Student's unpaired t test (where * denotes signiﬁcant inhibition by MG-132
(Pb0.05)). Data are mean+SEM values from 5 replicates.
Fig. 4.Molecularmechanisms underlying the effect of short-term pretreatment withMG-
132 on cytokine secretion. (A) Growth-arrested ASM cells were pretreatedwith vehicle or
MG-132 (10 μM) for 30 min and then stimulated with TNFα (10 ng/ml) for 0, 10, 20, 30
and 60 min. Cells were then lysed and analyzed by Western blotting using rabbit
polyclonal IgG antibodies against phosphorylated (Thr180/Tyr182) and total p38,
phosphorylated (Thr202/Tyr204) and total ERK, phosphorylated (Thr183/Tyr185) and total
JNK, MKP-1, α-tubulin (loading control) and IκB-α. Results are representative Western
blots from n=7 primary ASM cell lines. (B) ASM cells transfected with a NF-κB reporter
vector, pNF-κB-Luc, were pretreated with vehicle (empty histograms) or MG-132 (10 μM:
ﬁlled histograms) for 30 min, and then treated with vehicle or TNFα (10 ng/ml) for 6 h.
Cells were harvested and luciferase activities assessed. Data represent normalized
luciferase activity, relative to vehicle-treated cells (expressed as fold difference). Statistical
analysis was performed using the Student's unpaired t test (where § denotes a signiﬁcant
effect of TNFα, and * denotes signiﬁcant inhibition byMG-132 (Pb0.05)). Data aremean+
SEM values from 4 to 9 replicates. (C) Growth-arrested ASM cells were pretreated with
vehicle, SB203580 (1 μM), PD98059 (10 μM), or SP600125 (10 μM) for 30 min and then
stimulated with TNFα (10 ng/ml) for 24 h. Cell supernatants were collected and IL-
8 concentration determined by ELISA. Statistical analysis was performed using the
Student's unpaired t test (where * denotes signiﬁcant inhibition of TNFα-induced IL-
8 (Pb0.05)). Data are mean+SEM values from 14 to 22 replicates.thanwith TNFα only, but by this time the peak of MAPK had subsided;
thus, the effect of MG-132 on cytokine secretion (observed in Fig. 3A)
is temporally independent of its effect on MKP-1 upregulation.
Fig. 5. Proteasome inhibition increases MKP-1 and reduces TNFα-induced IL-6
secretion in a time-dependent manner. (A) Growth-arrested ASM cells were pretreated
with MG-132 (10 μM) for 0, 0.5, 1, 2, 4, 8, and 24 h and then left without further
treatment (empty histograms) or stimulated with TNFα (10 ng/ml: ﬁlled histograms) for
24 h. Cell supernatants were collected and IL-6 determined by ELISA. Statistical analysis
was performed using the Student's unpaired t test (where * denotes signiﬁcant
inhibition by MG-132 (Pb0.05)). Data are mean+SEM values from 4 replicates.
(B) Growth-arrested ASM cells were pretreated with MG-132 (10 μM) for 0, 0.5, 1, 2, 4,
8 and 24 h and then stimulated with TNFα (10 ng/ml) for 24 h. Vehicle-treated cells
served as an unstimulated control. Cells were then lysed and analyzed by Western
blotting using rabbit polyclonal IgG antibodies against phosphorylated (Thr180/Tyr182)
and total p38, phosphorylated (Thr202/Tyr204) and total ERK, phosphorylated (Thr183/
Tyr185) and total JNK, MKP-1, α-tubulin (loading control) and IκB-α. Results are
representative Western blots from n=3 primary ASM cell lines.
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responsible for the repression of cytokine secretion by short-term
pretreatment with MG-132. Both IL-6 and IL-8 are secreted by ASM
cells in response to TNFα via an NF-κB-dependent transcriptional
pathway [21,26]. Inhibition of the ubiquitin–proteasome system by
MG-132 reduces degradation of numerous key proteins, including
those responsible for gene expression in inﬂammation, such as IκB-α.
Because IκB-α inhibits the NF-κB pathway by restricting its location to
the cytoplasm and inhibiting its DNA binding activity, we now
explored whether inhibition of the NF-κB pathway was the molecular
mechanism responsible for the effect of short-term pretreatment with
MG-132 on cytokine secretion.
In Fig. 4A, we examined the degradation of IκB-α protein in
response to TNFα byWestern blotting. We show that the level of IκB-
α protein was greater when ASM cells were pretreated for 30 min
with the proteasome inhibitor MG-132 (Fig. 4A). By inhibiting the
proteasome, MG-132 reduced the degradation of IκB-α, demonstrated
by reappearance of IκB-α at 30 min. In parallel, we conﬁrmed that
MG-132 acts to inhibit the TNFα-induced NF-κB pathway in ASM cells
in experiments where we transiently transfected ASM cells with a
commercially available NF-κB luciferase reporter vector. In corrobo-
ration of our previous studies [21], we conﬁrm that TNFα signiﬁcantly
enhances NF-κB activity (Pb0.05: Fig. 4B). After pretreatment with
MG-132, TNFα-induced NF-κB activity was signiﬁcantly reduced from
22.4±3.5-fold to 6.5±2.3-fold (Pb0.05: Fig. 4B). Taken together,
these results demonstrate that TNFα-induced IL-6 secretion was
repressed by short-term pretreatment with MG-132, due to an
inhibitory effect on the NF-κB pathway, and was temporally
independent of its effect on MKP-1 expression.
Additionally, we wished to address why 30 min pretreatment with
MG-132 inhibits TNFα-induced IL-6, but not IL-8 secretion from ASM
cells. With this study we have demonstrated that MG-132 activates
ERK in ASM cells (Fig. 2A). Hence, it is possible that the ability of MG-
132 to inhibit IL-6, but not IL-8, reﬂected the involvement of the other
MAPK pathways in IL-8 production. We previously published that
TNFα-induced IL-6 secretion in ASM cells was independent of the ERK
and JNK pathways [5]. In a series of separate studies, researchers have
identiﬁed the MAPK signaling pathways underlying TNFα-induced IL-
8 secretion in ASM cells. The ERK [27] and p38 [21] pathways
predominate, with JNK-mediated signaling involved to a lesser extent
[28]. In Fig. 4C, we compare the relative contribution of MAPK family
members to TNFα-induced IL-8 secretion by employing speciﬁc
inhibitors of these pathways. Growth-arrested ASM cells were
pretreated with either the p38 inhibitor SB203580 (1 μM), the ERK
inhibitor PD98059 (10 μM), or the JNK inhibitor SP600125 (10 μM) for
30 min, and then stimulated with TNFα (10 ng/ml) for 24 h. Super-
natants were collected and IL-8 secretion determined by ELISA. In
corroboration of earlier work, we conﬁrm that pretreatment with
SB203580 or PD98059 inhibits IL-8 production in ASM cells (Pb0.05:
Fig. 4C). Inhibition of the JNK pathway with SP600125 (at 10 μM) had
no signiﬁcant effect on IL-8 secretion. Taken together, these results
suggest that despite inhibition of NF-κB activation by MG-132, MG-
132 also enhances ERK activation; thus, these opposing effects may
have led to unaffected IL-8 secretion in ASM cells.
3.5. Proteasome inhibition increases MKP-1 and reduces TNFα-induced
IL-6 secretion in a time-dependent manner
Because we found that short-term pretreatment of ASM cells with
MG-132 (for 30 min) had not resulted in sufﬁcient MKP-1 upregula-
tion at the crucial time point required to interrupt TNFα-induced
MAPK signaling (30 min: Fig. 4A), we now explored pretreatment of
ASM cells for up to 24 h with MG-132, and examined the resultant
effect on TNFα-induced IL-6 secretion.
As shown in Fig. 5A, pretreating ASM cells with MG-132 for longer
time periods before stimulation with TNFα resulted in a signiﬁcantinhibition of IL-6 secretion (Pb0.05). The degree of inhibition of IL-6
secretion was inversely correlated with MKP-1 protein expression
(Fig. 5B). Notably, when cells were pretreated for 24 h with MG-132,
resulting in robust MKP-1 upregulation (Fig. 5B), IL-6 secretion was
signiﬁcantly repressed to control levels (Fig. 5A: Pb0.05). The increase
in MKP-1 appeared to mirror the decrease in TNFα-induced p38
MAPK phosphorylation (especially at 8 and 24 h), demonstrating that
MG-132-induced MKP-1 shortens the temporal phosphorylation of
p38 MAPK in response to TNFα. JNK phosphorylation was also
repressed at 8 and 24 h (and ERK to a lesser extent), however, as
published previously [5], TNFα-induced IL-6 secretion in ASM cells
was independent of the JNK and ERK pathways.
3.6. MG-132 represses multiple cytokines implicated in asthma
To demonstrate the potential of proteasomal inhibition as an anti-
inﬂammatory approach in asthma we proﬁled the repressive effect of
MG-132 utilizing a cytokine array containing multiple cytokines,
chemokines and acute phase proteins (see map in Fig. 6A). Many of
these proteins have been implicated in asthma. Protein expression
was examined using supernatants fromASM cells (from n=3primary
Fig. 6. MG-132 represses multiple cytokines implicated in asthma. To proﬁle the repressive effect of MG-132 on a cytokine array (see map shown in (A)), we compared protein
expression in supernatants from ASM cells stimulated with TNFα for 24 h (B), with supernatants from cells that had been pretreated for 24 with MG-132 prior to stimulation (C).
(B and C) illustrate representative arrays (from n=3 primary ASM cell lines), while (D) demonstrates densitometric analysis where data are expressed as % TNFα-induced cytokine
(mean+SEM values from n=3 primary ASM cell lines) and statistical analysis performed using the Student's unpaired t test (where * denotes signiﬁcant inhibition by MG-132
(Pb0.05)).
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supernatants from cells that had been pretreated for 24 with MG-132
prior to stimulation (Fig. 6C). As demonstrated in Fig. 6B, a number of
proteins were found at high levels in supernatants from ASM cells
stimulated with TNFα, namely GROα, IL-6, IL-8, IP-10, MCP-1, MIF,
Serpin E1 and RANTES. In comparison, C5a, G-GSF and sICAM-1 were
found at relatively lower levels. Importantly, pretreatment with MG-
132 substantially represses the expression of the majority of these
cytokines, i.e. 8/11 (Fig. 6C). Following densitometric analysis
(Fig. 6D), we demonstrate that MG-132 signiﬁcantly repressed C5a,
GROα, sICAM-1, G-GSF IL-6, IP-10, MCP-1, MIF, RANTES (Pb0.05).Notably, MG-132 pretreatment reduced TNFα-induced IP-10, MCP-1
and RANTES by 89.1±2.7%, 86.0±0.3% and 91.1±3.3% respectively.
Like IL-8, Serpin E1 and MG-132 were not signiﬁcantly affected by
MG-132 pretreatment. Thus, using a cytokine array we show thatMG-
132 represses the secretion of multiple cytokines implicated in
asthma.
4. Discussion
The ubiquitin–proteasome system is a multi-subunit complex that
degrades various cellular proteins and plays an important role in
422 J.P. Moutzouris et al. / Biochimica et Biophysica Acta 1803 (2010) 416–423regulating the expression of numerous signal transduction molecules
involved in inﬂammation. The endogenous MAPK deactivator, MKP-1,
is one such protein degraded by this system. Inhibition of the
proteasome has previously been shown to substantially increase
MKP-1 [11,12]. Our study is the ﬁrst to demonstrate this in ASM, a
pivotal cell with important roles in airway remodeling.
MKP-1 is encoded by an immediate-early gene [24,29] and in our
study we show that inhibition of the proteasome with the inhibitor
MG-132 in ASM cells occurs via a combination of increased MKP-1
gene expression and inhibition of protein degradation by the
proteasome. In cell types apart from ASM, ERK activation can induce
MKP-1 expression [24] and stabilize the protein to degradation
[30,31]; however, we have shown that ERK does not contribute to the
upregulation of MKP-1 by MG-132 in this cell type.
We then examined the effects on MG-132 cytokine secretion by
ASM cells. Our results underscore the importance of the temporal
regulation ofMAPK andnegative feedback control byMKP-1.We show
that short-term (30 min) preincubation of ASM cells withMG-132 had
not yet resulted in sufﬁcientMKP-1 upregulation to have an inhibitory
effect onMAPK activation orMAPK-mediated cellular events. This was
simply due to timing, since the peak of MAPK activation had occurred
before the induction and expression ofMKP-1. Under these conditions,
TNFα-induced IL-6 secretion was repressed by MG-132, due to an
inhibitory effect on IκB-α degradation and the NF-κB pathway, and
was temporally independent of its effect on MKP-1 expression.
However, when cells were pretreated for up to 24 h with proteasome
inhibitor, we show that MG-132-induced MKP-1 represses phosphor-
ylation of p38MAPK in response to TNFα stimulation, and reduces IL-6
secretion from ASM, in a time-dependent manner.
To underscore the potential of proteasome inhibition as an anti-
inﬂammatory strategy to repress cytokine secretion by ASM cells we
employed a cytokine array to simultaneously measure 36 cytokines,
chemokines and acute phase proteins. We show that a number of
proteins were found at high levels in supernatants from ASM cells
stimulated with TNFα, namely GROα, IL-6, IL-8, IP-10, MCP-1, MIF,
Serpin E1 and RANTES; while C5a, G-GSF and sICAM-1 were found at
relatively lower levels. Many of these proteins have been implicated in
asthma (reviewed in [32,33]). Importantly, long-term treatment with
MG-132 signiﬁcantly repressed the secretion of the majority of these
proteins. For example, MG-132 inhibited secretion of IP-10 by ∼90%;
IP-10 is a CXC chemokine secreted in elevated amounts from the ASM
of asthmatics and responsible for the attraction ofmast cells [34].MCP-
1 and RANTES, two important chemokines responsible for the
chemoattraction of monocytes and eosinophils in airway inﬂamma-
tion in asthma [32], were also repressed by 80–90% following MG-132
treatment. MAPK-mediated pathways are responsible for secretion of
these chemokines from ASM cells [25,28]([35]. Given that cytokines
play a major role in perpetuating airway inﬂammation in asthma and
that ASM is a pivotal immunomodulatory cell in the asthmatic airway,
our study demonstrating thatMG-132 inhibits cytokine secretion from
ASM cells is among the ﬁrst to highlight the potential of the
proteasome as a therapeutic target in asthma.
In summary, proteasomal inhibition represents an effective means
to increase protein levels of the endogenousMAPK deactivator MKP-1
in ASM cells. Given the pivotal role played by MAPKs in asthma and
the critical role of MKP-1 in their regulation, further studies
investigating the strategies designed to speciﬁcally upregulate MKP-
1 may demonstrate the potential of MKP-1 as a novel therapeutic
target in asthma.
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